LIMA, Peru, Jan. 14 /PRNewswire/ -- The National Cancer Coalition (NCC) and Wyeth Pharmaceuticals (Wyeth) are pleased to announce a pilot program to assist cancer patients in Latin America with donations of Wyeth's cancer-related medicines Mylotarg(TM) (gemtuzumab ozogamicin for injection) and Neumega(TM) (oprelvekin).
United States Ambassador Michael McKinley and the Peruvian Health Ministry participated in a hand-over event held at the Instituto Nacional de Enfermadades Neoplacias (INEN) in Lima, along with representatives from National Cancer Coalition, Wyeth Pharmaceuticals, INEN, and the Peruvian media. This donation to INEN, which is the largest public cancer hospital in Peru, consists of life-saving medicines valued at over $500,000.
Ambassador McKinley stated, "The event we are celebrating today is very important for several reasons. First, because this donation is the light of hope for many cancer patients in Peru who, due to the large quantity of medicines being donated today, will have access to life-saving treatment. In addition, this event is very special because it underscores the importance of public-private partnerships and the concrete gains that can be achieved with these partnerships to meet the critical health care needs of our citizens."
Eduardo Nieto, President, Wyeth Pharmaceuticals, Latin America, commented, "Wyeth is dedicated to aiding patients in need, and we are honored to be partnering with NCC in this initiative to provide oncology medicines to underserved patients in Peru."
"National Cancer Coalition is pleased that this new program with Wyeth Pharmaceuticals will lead to greater oncology resources for patients in the developing world. Through this donation, it is anticipated that over 100 Peruvian leukemia patients will be helped at INEN this year. NCC looks forward to expanding our medicine donation initiatives with Wyeth, as we jointly seek to help pa
|SOURCE National Cancer Coalition|
Copyright©2009 PR Newswire.
All rights reserved